Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05516732
Other study ID # 2020-21-16
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 1, 2022
Est. completion date June 30, 2024

Study information

Verified date November 2023
Source University of Exeter
Contact Marios Politis, Professor
Phone 07503741242
Email M.Politis@exeter.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, the investigators aim to provide a deeper understanding of Parkinson's disease and find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of Parkinson's disease symptoms


Description:

The purpose of this study is to find a biomarker for Parkinson's disease (PD). A biomarker is an indicator of the presence of a disease, that can be measured, and that is able to give information about the progression, or severity, of it. The study visits will take place in London. There are three locations on Hammersmith hospital campus, that are located near to each other. The NIHR Imperial Clinical Research Facility and Invicro London for clinical and MRI and PET assessments, and Imperial Healthcare Nuclear Medicine Department for the SPECT scan. Participants will attend 5 visits in a 3 month period. These visits include an initial consent and assessment visit where some blood samples will also be taken. The second visit involves a PET scan with the tracer DASB along with an MRI scan. The third visit involves two PET scans one in the morning, with CIMBI tracer, an injection of Dexamphetamine, and then a second with CIMBI tracer to make a comparison. The fourth visit involves a SPECT scan, and the fifth visit is optional and would be for a lumbar puncture visit. Each visit will last around 6 hours.


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers
Gender All
Age group 25 Years to 85 Years
Eligibility Inclusion criteria- - Subjects must understand the nature of the study and must provide signed and dated written HRA-approved informed consent in accordance with local regulations before any protocol-specific screening procedures are performed; - Males and females, age 25-85 years, inclusive; - Women of child-bearing potential must use protocol-defined contraceptive measures and must have a negative ß-hCG test at screening. For sexually active subjects (except females of non-childbearing potential-e.g., at least 2 years postmenopausal or surgically sterile), condoms should be used in addition to other birth control methods for the duration of the study and for 3 months after the last administration of PET or SPECT ligands. These patients must be willing to remain on their current form of contraception for the duration of the study. All male subjects must agree to refrain from donating sperm for the duration of the study and for 3 months after the last administration of PET or SPECT ligands. Sexually active male subjects must agree to use condoms to protect their partners from becoming pregnant for the duration of the study and for 3 months after the last administration of PET or SPECT ligands (i.e. for 15 consecutive months following baseline PET and SPECT scans); agree to ensure that they and their partners are routinely using a medically approved contraceptive method. It is important that male subjects not impregnate others for the duration of the study and for 3 months after the last administration of PET or SPECT ligands; - Able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures; - Adequate visual and auditory acuity to complete the psychological testing; - In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study. Exclusion criteria - - Subjects lacking capacity according to investigator judgement; - Subjects taking serotonin acting drugs such as antidepressants (i.e. tricyclic or selective serotonin reuptake inhibitors etc.); - Pregnancy or breastfeeding or intent to become pregnant in the next 18 months; - Subjects with current or a recent history of drug or alcohol abuse/dependence; - Subjects who have other neurological disorders and known intracranial co-morbidities such as stroke, hemorrhage, space-occupying lesions; - Presence of any clinically significant medical condition (including cardiovascular, respiratory, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other disease) that, based on the judgment of the investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject's ability to complete the study, or could influence the study results; - History of suicidal behaviour or active suicidal ideation; - Within 1 year prior to screen or between screen and baseline (Day -1), any of the following: myocardial infarction; hospitalization for congestive heart failure; hospitalization for, or symptoms of, unstable angina; or syncope not related to PD; - History or presence of renal disease or impaired renal function; - Clinically important infection (e.g., chronic, persistent, or acute infection) within 30 days prior to screen or between screen and baseline (Day -1); - History of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma of the skin; - Clinically significant blood clotting or bleeding disorder, including clinically significant abnormal findings in laboratory assessments of coagulation or hematology; - Use of antipsychotic medication within 3 months prior to screen or between screen and baseline (Day -1); - Use of any anticoagulant within 30 days prior to baseline and follow-up PET scans; - Use of any oral corticosteroid within 30 days prior to baseline and follow-up PET scans; - Use of metoclopramide within 30 days prior to baseline and follow-up (Day -1); - Use of any thyroid medication within 30 days prior to baseline and follow-up (Day -1); - Regular use (e.g., taken > 3 days/week) of narcotic pain medications within 30 days prior to baseline and follow-up (Day -1); - Presence of any of the following MRI contraindications: pacemaker; cardiac defibrillator; spinal cord or vagus nerve stimulator; aneurysm clip; artificial heart valve; recent coronary or carotid stent; ear implant; CSF shunt; other implanted medical device (e.g., Swan-Ganz catheter, insulin pump); or metal fragments or foreign objects in the eyes, skin, or body; - Negative modified Allen test in both hands, unless the brachial artery is used for arterial cannulation; - Claustrophobia or history of back pain that makes prolonged laying on the PET or MRI scanner intolerable; - History of severe skin allergy; - Patients who had previous surgery for PD (including but not limited to deep brain stimulation [DBS] or cell transplantation); - Patients who are treated with duodopa or apomorphine; - Initiation or change in pharmacologic therapy for symptoms of PD within 30 days prior to screen or between screen and baseline and follow-up (Day -1). - GDS score greater than or equal to 10 (GDS score of 5 - 9 requires Investigator discretion to enter study). - STAI Form Y-1 greater than or equal to 54 requires Investigator discretion to enter study.

Study Design


Intervention

Other:
Positron Emission Tomography (PET) scan using CIMBI-36 tracer
This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
Magnetic Resonance Imaging (MRI) Scan
MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
Positron Emission Tomography (PET) scan using DASB tracer
To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
FP-CIT Single-photon Emission Computed Tomography (SPECT) scan
A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
Lumbar puncture
A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)

Locations

Country Name City State
United Kingdom University Of Exeter Exeter Devon

Sponsors (1)

Lead Sponsor Collaborator
University of Exeter

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) To determine if there is a correlation with neuropsychological and behavioural evaluation. A rating tool used to gauge the course of Parkinson's disease in patients 3 Weeks
Other Montreal Cognitive Assessment (MOCA) to determine if there is a correlation with neuropsychological and behavioural evaluation A cognitive screening test designed to assist in the detection of mild cognitive impairment. Scored out of 30. 3 Weeks
Other Cambridge Neuropsychological Test Automated Battery (CANTAB) to determine if there is a correlation with neuropsychological and behavioural evaluation Administered to detect cognitive issues & brain disorders efficiently. 3 Weeks
Other Symbol Digit Modalities Test (SDMT) to determine if there is a correlation with neuropsychological and behavioural evaluation To be used in screening for organic cerebral dysfunction sored out of 110 3 Weeks
Other Beck Depression Inventory-II (BDI-II) to determine if there is a correlation with neuropsychological and behavioural evaluation A brief, self-report inventory designed to measure the severity of depression symptomatology 3 Weeks
Other State-Trait Anxiety Inventory (STAI) to determine if there is a correlation with neuropsychological and behavioural evaluation A commonly used measure of trait and state anxiety. Used to diagnose anxiety and to distinguish it from depressive syndromes. 3 Weeks
Other University of Pennsylvania Smell Identification Test to determine if there is a correlation with neuropsychological and behavioural evaluation This is used to test the function of an individual's olfactory system 3 Weeks
Other Movement Disorder Society- Non-Motor Symptoms scale for Parkinson's Disease MDS-NMSS to determine if there is a correlation with neuropsychological and behavioural evaluation This is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease 3 Weeks
Other Scales for Outcomes in Parkinson's Disease-Autonomic questionnaire - Autonomic Dysfunction (SCOPA-AUT) to determine if there is a correlation with neuropsychological and behavioural evaluation A 25 item assessment to evaluate autonomic symptoms in patients with Parkinson's disease 3 Weeks
Primary DASB (a marker of Serotonin transporter) used to quantify in vivo pathology of serotonin To quantify serotonergic pathology with [11C]3-amino-4-(2- imethylaminomethylphenylsulfanyl)-benzonitrile (DASB) Positron Emission Tomography (PET) 3 Weeks
Primary SPECT to measure brain molecular pathology To quantify serotonergic pathology with [11C]DASB PET and dopaminergic pathology with Single-photon Emission Computed Tomography (SPECT) 3 Weeks
Primary Magnetic Resonance Imaging (MRI) Magnetic Resonance Imaging (MRI) to view structural and microstructural changes and structural connectivity. 3 Weeks
Primary CIMBI to measure serotonin release CIMBI-36 can be interpreted to show serotonin release capacity both quantifiably and locational. 3 weeks
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A